Cargando…

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

Detalles Bibliográficos
Autores principales:	King, Lisa A., Lameris, Roeland, de Gruijl, Tanja D., van der Vliet, Hans J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256414/ https://www.ncbi.nlm.nih.gov/pubmed/30519237 http://dx.doi.org/10.3389/fimmu.2018.02606

Ejemplares similares

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1
por: Grabowska, Joanna, et al.
Publicado: (2021)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
por: Veluchamy, John P., et al.
Publicado: (2017)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
por: Bedard, Melissa, et al.
Publicado: (2017)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Distinct and Overlapping Effector Functions of Expanded Human CD4(+), CD8α(+) and CD4(-)CD8α(-) Invariant Natural Killer T Cells
por: O'Reilly, Vincent, et al.
Publicado: (2011)

Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy
por: Shissler, Susannah C., et al.
Publicado: (2017)

Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies
por: Lam, Pui Yeng, et al.
Publicado: (2017)

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
por: Fujii, Shin-ichiro, et al.
Publicado: (2003)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids
por: Shimamura, Michio, et al.
Publicado: (2017)

Invariant Natural Killer T and Mucosal-Associated Invariant T Cells in Asthmatic Patients
por: Lezmi, Guillaume, et al.
Publicado: (2018)

Antitumor Responses of Invariant Natural Killer T Cells
por: Altman, Jennie B., et al.
Publicado: (2015)

Immunometabolic Activation of Invariant Natural Killer T Cells
por: Ververs, Francesca A., et al.
Publicado: (2018)

Antigen specificity of invariant natural killer T-cells
por: Birkholz, Alysia M., et al.
Publicado: (2015)

The two faces of invariant natural killer T cells
por: Walton, Emma L.
Publicado: (2015)

Metabolism in Invariant Natural Killer T Cells: An Overview
por: Yarosz, Emily L., et al.
Publicado: (2021)

Invariant natural killer T cells in lung diseases
por: Jeong, Dongjin, et al.
Publicado: (2023)

Spleen-Resident CD4(+) and CD4(−) CD8α(−) Dendritic Cell Subsets Differ in Their Ability to Prime Invariant Natural Killer T Lymphocytes
por: Bialecki, Emilie, et al.
Publicado: (2011)

Lineage Differentiation Program of Invariant Natural Killer T Cells
por: Kwon, Dong-il, et al.
Publicado: (2017)

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity
por: Van Kaer, Luc, et al.
Publicado: (2018)

CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes
por: Galli, Grazia, et al.
Publicado: (2003)

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e77qupfikjulogperspnsf7gua